HATTORI Noboru Kitano Hospital The Tazuke Kofukai Medical Research Institute., Fifth Department of Oncology Department of Thoracic Surgery, Chief-Researcher, 医学研究所・第5研究部, 主任研究員 (00283169)
MIYAKE Masayuki Kitano Hospital The Tazuke Kofukai Medical Research Institute., Fifth Department of Oncology Department of Thoracic Surgery, Director, 医学研究所・第5研究部, 部長 (90250076)
|Budget Amount *help
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2003: ¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 2002: ¥2,200,000 (Direct Cost: ¥2,200,000)
Initially, we tried to establish many kinds of cell lines of lung cancer. The previous experiments showed that mixing 50% matrigel in this collagen was the most efficient for establishment of the cell lines. Furthermore, adding 10% of patients' serum in the above mixture made it easier to establish the cell line. Using this method, three kinds of AAH were established, which was the first success of establishment AAH cell lines in the collagen gel, and then we succeeded in almost 10 times cultures. At this stage, it was possible to analyze the mutation of p53. But, all three cases had wild type of p53 gene, and abnormality of p53 related genes for example, p21was not found. We also established cell lines on the lung cancers from the point of view of pathology. It was succeeded to establish 10 cell lines in Stage I lung cancer and 9 cell lines in Stage II. We tried to establishl3 cell lines in Stage III lung cancer that did chemotherapy before the operation, in contrast, only 4 cell lines were established because most of the parts were necrotic region. Then, 6 kinds of cell lines in StageIV were established from the specimens of metastasis region. From these points, we examined mutations of p53, not from extracted DNA from the resected specimens, but from those cell lines, which is important to avoid the contamination of normal cells. However, we could not find any relationships between mutations of p53 and stages. And also, no significant relationships between diseases free survival and p53 mutations were found. On the other hand, we could not find the significant relationship of anticancer drug sensitivity and the effect on the patients using the same drugs in the patients with the relapse of StageIII and StageIV lung cancer.